Rituximab as induction therapy after renal transplantation: A randomized, double-blind, placebo-controlled study of efficacy and safety

American Journal of Transplantation

Volumn 15, Issue 2, 2015, Pages 407-416

  Van Den Hoogen, M W F ^a,b   Kamburova, E G ^a   Baas, M C ^a   Steenbergen, E J ^a   Florquin, S ^a   Koenen, H J P M ^a   Joosten, I ^a   Hilbrands, L B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clinical research practice; fusion proteins and monoclonal antibodies: B cell specific; immunosuppressant; kidney transplantation nephrology; rejection: acute; rejection: antibody mediated (ABMR); rejection: T cell mediated (TCMR)

Indexed keywords

ALEMTUZUMAB; COTRIMOXAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PANEL REACTIVE ANTIBODY; PLACEBO; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; B LYMPHOCYTE; BIOPSY; GRAFT REJECTION; INCIDENCE; KIDNEY; MIDDLE AGED; PATHOLOGY; REMISSION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; BIOPSY; DOUBLE-BLIND METHOD; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84921451815     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13052     Document Type: Article

References (32)

1. Chapman JR, O'Connell PJ, Nankivell BJ., Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015-3026.
2. Meier-Kriesche HU, Arndorfer JA, Kaplan B., Association of antibody induction with short-and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769-772.
3. Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010; CD003897.
4. Gebel HM, Bray RA, Nickerson P., Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3: 1488-1500.
5. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125-138.
6. Scott DL, Wolfe F, Huizinga TW., Rheumatoid arthritis. Lancet 2010; 376: 1094-1108.
7. van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011; 63: 1507-1516.
8. Kimby E., Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31: 456-473.
9. Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G., Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418-2428.
10. Tydén G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I., ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145-148.
11. ten Hoor GM, Coopmans M, Allebes WA., Specificity and Ig class of preformed alloantibodies causing a positive crossmatch in renal transplantation. The implications for graft survival. Transplantation 1993; 56: 298-304.
12. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152: 726-732.
13. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
14. van den Hoogen MW, Hilbrands LB., More on B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 361: 1215-1216.
15. Tydén G, Genberg H, Tollemar J, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325-1329.
16. Clatworthy MR, Watson CJ, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360: 2683-2685.
17. Zarkhin V, Lovelace PA, Li L, Hsieh SC, Sarwal MM., Phenotypic evaluation of B-cell subsets after rituximab for treatment of acute renal allograft rejection in pediatric recipients. Transplantation 2011; 91: 1010-1018.
18. Lanio N, Sarmiento E, Gallego A, et al. Alterations of naive and memory B-cell subsets are associated with risk of rejection and infection in heart recipients. Transpl Int 2013; 26: 800-812.
19. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP., The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7: 402-407.
20. Kamburova EG, Koenen HJ, Borgman KJ, ten Berge IJ, Joosten I, Hilbrands LB., A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant 2013; 13: 1503-1511.
21. Kamburova EG, Koenen HJ, Boon L, Hilbrands LB, Joosten I., In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant 2012; 12: 341-350.
22. Zachary AA, Lucas DP, Montgomery RA, Leffell MS., Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA. Transplantation 2013; 95: 701-704.
23. Kohei N, Hirai T, Omoto K, Ishida H, Tanabe K., Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12: 469-476.
24. Wolach O, Bairey O, Lahav M., Late-onset neutropenia after rituximab treatment: Case series and comprehensive review of the literature. Medicine (Baltimore) 2010; 89: 308-318.
25. Genberg H, Kumlien G, Wennberg L, Berg U, Tydén G., ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: A 3-year follow-up. Transplantation 2008; 85: 1745-1754.
26. Wilpert J, Fischer KG, Pisarski P, et al. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. Nephrol Dial Transplant 2010; 25: 3778-3786.
27. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM., A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008; 8: 2607-2617.
28. Tydén G, Ekberg H, Tufveson G, Mjornstedt L., A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: A 3-year follow-up. Transplantation 2012; 94: e21-e22.
29. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1-155.
30. Kahwaji J, Sinha A, Toyoda M, et al. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 2011; 6: 2894-2900.
31. Vo AA, Wechsler EA, Wang J, et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant 2008; 8: 144-149.
32. Levey AS, Coresh J, Greene T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772.